A Phase II, Multicenter, Open-label, Randomized Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 03 May 2018 Planned End Date changed from 24 Nov 2020 to 10 Mar 2022.
- 03 May 2018 Planned primary completion date changed from 24 Nov 2020 to 10 Mar 2022.